cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2026-41-3-19-26cardiotomsk-3287Research ArticleОБЗОРЫREVIEWSПептиды – кардиопротекторные препараты будущего. ИнтермединPeptides – cardioprotective drugs of the future. Intermedinhttps://orcid.org/0000-0003-1808-556XМухомедзяновА. В.MukhomedzyanovA. V.

Мухомедзянов Александр Валерьевич - канд. мед. наук, научный сотрудник, лаборатория экспериментальной кардиологии, НИИ кардиологии Томского НИМЦ.

634012, Томск, ул. Киевская, 111а

Alexander V. Mukhomedzyanov - Cand. Sci. (Med.), Research Scientist, Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk NRMC.

111a, Kievskaya str., Tomsk, 634012

sasha_m91@mail.ruhttps://orcid.org/0000-0002-1607-1482ПоповС. В.PopovS. V.

Попов Сергей Валентинович - д-р мед. наук, профессор, академик РАН, директор НИИ кардиологии Томского НИМЦ.

634012, Томск, ул. Киевская, 111а

Sergey V. Popov - Dr. Sci. (Med.), Academician of the Russian Academy of Sciences, Director, Cardiology Research Institute, Tomsk NRMC.

111a, Kievskaya str., Tomsk, 634012

press@cardio-tomsk.ruhttps://orcid.org/0000-0002-6020-1598МасловЛ. Н.MaslovL. N.

Маслов Леонид Николаевич - д-р мед. наук, профессор, заведующий лабораторией экспериментальной кардиологии, НИИ кардиологии Томского НИМЦ.

634012, Томск, ул. Киевская, 111а

Leonid N. Maslov - Dr. Sci. (Med.), Professor, Head of the Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk NRMC.

111a, Kievskaya str., Tomsk, 634012

maslov@cardio-tomsk.ruhttps://orcid.org/0009-0002-5073-9543ЛатоновВ. Р.LatonovV. R.

Латонов Владислав Русланович - старший лаборант, лаборатория экспериментальной кардиологии, НИИ кардиологии Томского НИМЦ.

634012, Томск, ул. Киевская, 111а

Vladislav R. Latonov - Senior Laboratory Assistant, Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk NRMC.

111a, Kievskaya str., Tomsk, 634012

latonovvr@mail.ruhttps://orcid.org/0000-0003-2264-1928НарыжнаяН. В.NaryzhnayaN. V.

Нарыжная Наталья Владимировна - д-р мед. наук, ведущий научный сотрудник, лаборатория экспериментальной кардиологии, НИИ кардиологии Томского НИМЦ.

634012, Томск, ул. Киевская, 111а

Natalia V. Naryzhnaya - Dr. Sci. (Med.)., Leading Research Scientist, Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk NRMC.

111a, Kievskaya str., Tomsk, 634012

natalynar@yandex.ruhttps://orcid.org/0000-0002-8939-2340ПодоксеновЮ. К.PodoxenovYu. K.

Подоксенов Юрий Кириллович - д-р мед. наук, ведущий научный сотрудник, отделение сердечно-сосудистой хирургии, НИИ кардиологии Томского НИМЦ.

634012, Томск, ул. Киевская, 111а

Yuri K. Podoksenov - Dr. Sci. (Med.)., Leading Research Scientist, Department of Cardiovascular Surgery, Research Institute of Cardiology, Tomsk NRMC.

111a, Kievskaya str., Tomsk, 634012

uk@cardio-tomsk.ruНаучно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук (НИИ кардиологии Томского НИМЦ)РоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Cardiology Research Institute, Tomsk NRMC)Russian Federation2026021020264131926Copyright © Мухомедзянов А.В., Попов С.В., Маслов Л.Н., Латонов В.Р., Нарыжная Н.В., Подоксенов Ю.К., 20262026Мухомедзянов А.В., Попов С.В., Маслов Л.Н., Латонов В.Р., Нарыжная Н.В., Подоксенов Ю.К.Mukhomedzyanov A.V., Popov S.V., Maslov L.N., Latonov V.R., Naryzhnaya N.V., Podoxenov Y.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/3287

Несмотря на несомненные успехи, достигнутые в лечении острого инфаркта миокарда (ОИМ), проблема повышения эффективности лечения этого заболевания остается по-прежнему актуальной. По мере внедрения в клиническую практику чрескожного коронарного вмешательства на первый план выходят реперфузионные повреждения сердца, в отношении которых лекарственные препараты, применяемые для лечения ОИМ, малоэффективны. По нашему мнению, более действенными препаратами для предупреждения реперфузионного повреждения сердца могут оказаться полипептиды, в частности интермедин (адреномедуллин-2). Анализ представленных в статье данных свидетельствует о том, что этот полипептид способен предупреждать реперфузионное повреждение сердца и усиливать толерантность изолированных кардиомиоцитов к гипоксии/реоксигенации. Показано, что кардиопротекторный и цитопротекторный эффект интермедина связан с активацией рецептора RAMP2 и стимуляцией ряда киназ. Кардиопротекторный эффект зависит от ингибирования апоптоза кардиомиоцитов и стимуляции аутофагии кардиомиоцитов. В статье продемонстрирована целесообразность проведения доклинических исследований инфаркт-лимитирующего эффекта энзимоустойчивых аналогов интермедина у животных с коронароокклюзией и реперфузией.

Цель обзора: анализ опубликованных данных о кардиопротекторном эффекте интермедина. Поиск литературы осуществлялся в базах данных PubMed и eLibrary с использованием запросов «intermedin», «cardioprotective effect of intermedin», «adrenomedullin-2», «myocardial ischemia reperfusion», «cardiomyocytes hypoxia reoxygenation». Поиск проводился без строгих временных ограничений с акцентом на экспериментальные и обзорные работы, посвященные кардиопротекторным эффектам интермедина. В обзор включены наиболее релевантные исследования (48 источников).

Despite the undoubted successes achieved in the treatment of acute myocardial infarction (AMI), the problem of increasing the effectiveness of treating this disease remains relevant. Despite the undoubted successes achieved in the treatment of AMI, the problem of increasing the effectiveness of treating this disease remains relevant. With the introduction of percutaneous coronary intervention into clinical practice, myocardial reperfusion injury comes to the fore, for which drugs used to treat AMI are of little effectiveness. In our opinion, polypeptides, particularly intermedin (adrenomedullin-2), may prove to be more effective drugs for preventing myocardial reperfusion injury. Analysis of the data presented in the article indicates that this polypeptide can prevent myocardial reperfusion injury and enhance the tolerance of isolated cardiomyocytes to hypoxia/reoxygenation. It has been shown that the cardioprotective and cytoprotective effect of intermedin is associated with the activation of the RAMP2 receptor and the stimulation of several kinases. The cardioprotective effect depends on the inhibition of cardiomyocyte apoptosis and the stimulation of cardiomyocyte autophagy. The article demonstrates the expediency of conducting preclinical studies of the infarct-limiting effect of enzyme-resistant analogs of intermedin in animals with coronary occlusion and reperfusion.

Aim: To assess published data on the cardioprotective effect of intermedin. Literature search was carried out in the PubMed and eLibrary databases using the queries "intermedin", "cardioprotective effect of intermedin", "adrenomedullin-2", "myocardial ischemia reperfusion", "cardiomyocytes hypoxia reoxygenation". The search was conducted without strict time limitations, with an emphasis on experimental and review works dedicated to the cardioprotective effects of intermedin. The review includes the most relevant studies (48 sources).

интермединсердцеишемияреперфузиякиназыапоптозаутофагияintermedinheartischemiareperfusionkinasesapoptosisautophagyРабота выполнена при финансовой поддержке гранта Российского научного фонда № 23-65-10017. Раздел, посвященный нерешенным вопросам, подготовлен в рамках государственного задания № 122020300042-4 Министерства науки и высшего образования Российской Федерации.The study was supported by the Russian Science Foundation grant No. 23-65-10017. Section dedicated to unresolved issues was prepared in the framework of the state assignment 122020300042-4 of Ministry of Science and Higher Education of the Russian Federation.ReferencesCurrey E.M., Falconer N., Isoardi K.Z., Barras M. Impact of pharmacists during in-hospital resuscitation or medical emergency response events: A systematic review. Am. J. Emerg. Med. 2024;75:98–110. DOI: 10.1016/j.ajem.2023.10.020 EDN: NPMEYDCurrey E.M., Falconer N., Isoardi K.Z., Barras M. Impact of pharmacists during in-hospital resuscitation or medical emergency response events: A systematic review. Am. J. Emerg. Med. 2024;75:98–110. DOI: 10.1016/j.ajem.2023.10.020 EDN: NPMEYDAshraf S., Farooq U., Shahbaz A., et al. Factors Responsible for Worse Outcomes in STEMI Patients with Early vs Delayed Treatment Presenting in a Tertiary Care Center in a Third World Country. Curr. Probl. Cardiol. 2024;49(1):102049. DOI: 10.1016/j.cpcardiol.2023.102049 EDN: NOJLBMAshraf S., Farooq U., Shahbaz A., et al. Factors Responsible for Worse Outcomes in STEMI Patients with Early vs Delayed Treatment Presenting in a Tertiary Care Center in a Third World Country. Curr. Probl. Cardiol. 2024;49(1):102049. DOI: 10.1016/j.cpcardiol.2023.102049 EDN: NOJLBMNanavaty D., Sinha R., Kaul D., et al. Impact of COVID-19 on Acute Myocardial Infarction: A National Inpatient Sample Analysis. Curr. Probl. Cardiol. 2024;49(1):102030. DOI: 10.1016/j.cpcardiol.2023.102030 EDN: TFNRTONanavaty D., Sinha R., Kaul D., et al. Impact of COVID-19 on Acute Myocardial Infarction: A National Inpatient Sample Analysis. Curr. Probl. Cardiol. 2024;49(1):102030. DOI: 10.1016/j.cpcardiol.2023.102030 EDN: TFNRTOHti Lar Seng N.S., Zeratsion G., Pena Zapata O.Y., et al. Utility of Cardiac Troponins in Patients with Chronic Kidney Disease. Cardiol. Rev. 2024;32(1):62-70. DOI: 10.1097/CRD.0000000000000461 EDN: FCORCTHti Lar Seng N.S., Zeratsion G., Pena Zapata O.Y., et al. Utility of Cardiac Troponins in Patients with Chronic Kidney Disease. Cardiol. Rev. 2024;32(1):62-70. DOI: 10.1097/CRD.0000000000000461 EDN: FCORCTLuo Q., Sun W., Li Z., et al. Biomaterials-mediated targeted therapeutics of myocardial ischemia-reperfusion injury. Biomaterials. 2023;303:122368. DOI: 10.1016/j.biomaterials.2023.122368 EDN: IDLSVELuo Q., Sun W., Li Z., et al. Biomaterials-mediated targeted therapeutics of myocardial ischemia-reperfusion injury. Biomaterials. 2023;303:122368. DOI: 10.1016/j.biomaterials.2023.122368 EDN: IDLSVEМотова А.В., Каретникова В.Н., Осокина А.В. и др. Инфаркт миокарда 2-го типа: особенности диагностики в реальной клинической практике. Сибирский журнал клинической и экспериментальной медицины. 2022;37(3):75–82. DOI: 10.29001/2073-8552-2022-37-3-75-82 EDN: LFHJYBMotova A.V., Karetnikova V.N., Osokina A.V., et al. Type 2 myocardial infarction: Diagnostic features in real clinical practice. Siberian Journal of Clinical and Experimental Medicine. 2022;37(3):75–82. (In Russ.). DOI: 10.29001/2073-8552-2022-37-3-75-82 EDN: LFHJYBВышлов Е.В., Алексеева Я.В., Усов В.Ю. и др. Синдром микрососудистого повреждения миокарда у пациентов с первичным инфарктом миокарда с подъемом сегмента ST: распространенность и связь с клиническими характеристиками. Сибирский журнал клинической и экспериментальной медицины. 2022;37(1):36–46. DOI: 10.29001/2073-8552-2021-36-4-36-46 EDN: LOLFFWVyshlov E.V., Alexeeva Ya.A., Ussov W.Yu., et al. Phenomena of microvascular myocardial injury in patients with primary ST-segment elevation myocardial infarction: Prevalence and association with clinical characteristics. Siberian Journal of Clinical and Experimental Medicine. 2022;37(1):36–46. DOI: 10.29001/2073-8552-2021-36-4-36-46 EDN: LOLFFWПантелеев О.О., Рябов В.В. Кардиогенный шок – что нового? Сибирский журнал клинической и экспериментальной медицины. 2021;36(4):45–51. DOI: 10.29001/2073-8552-2021-36-4-45-51 EDN: TGEJXOPanteleev O.O., Ryabov V.V. Cardiogenic shock: What's new? Siberian Journal of Clinical and Experimental Medicine. 2021;36(4):45–51. (In Russ.). DOI: 10.29001/2073-8552-2021-36-4-45-51 EDN: TGEJXOLi M., Hu L., Li L. Research progress of intra-aortic balloon counterpulsation in the treatment of acute myocardial infarction with cardiogenic shock: A review. Medicine (Baltimore). 2023;102(49):e36500. DOI: 10.1097/MD.0000000000036500 EDN: TFIQTXLi M., Hu L., Li L. Research progress of intra-aortic balloon counterpulsation in the treatment of acute myocardial infarction with cardiogenic shock: A review. Medicine (Baltimore). 2023;102(49):e36500. DOI: 10.1097/MD.0000000000036500 EDN: TFIQTXMcCartney P.J., Berry C. Redefining successful primary PCI. Eur. Heart J. Cardiovasc. Imaging. 2019;20(2):133–135. DOI: 10.1093/ehjci/jey159 EDN: WVYQDLMcCartney P.J., Berry C. Redefining successful primary PCI. Eur. Heart J. Cardiovasc. Imaging. 2019;20(2):133–135. DOI: 10.1093/ehjci/jey159 EDN: WVYQDLMaslov L.N., Popov S.V., Mukhomedzyanov A.V., et al. Reperfusion Cardiac Injury: Receptors and the Signaling Mechanisms. Curr. Cardiol. Rev. 2022;18(5):63–79. DOI: 10.2174/1573403X18666220413121730 EDN: JMTGVGMaslov L.N., Popov S.V., Mukhomedzyanov A.V., et al. Reperfusion Cardiac Injury: Receptors and the Signaling Mechanisms. Curr. Cardiol. Rev. 2022;18(5):63–79. DOI: 10.2174/1573403X18666220413121730 EDN: JMTGVGRoh J., Chang C.L., Bhalla A., et al. Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes. J. Biolog. Chem. 2004;279(8):7264–7274. DOI: 10.1074/jbc.M305332200Roh J., Chang C.L., Bhalla A., et al. Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes. J. Biolog. Chem. 2004;279(8):7264–7274. DOI: 10.1074/jbc.M305332200Takei Y., Inoue K., Ogoshi M., et al. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett. 2004;556(1-3):53–58. DOI: 10.1016/S0014-5793(03)01368-1 EDN: EU-RRGDTakei Y., Inoue K., Ogoshi M., et al. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett. 2004;556(1-3):53–58. DOI: 10.1016/S0014-5793(03)01368-1 EDN: EU-RRGDChang C.L., Roh J., Hsu S.Y.T. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides (N.Y.). 2004;25(10):1633–1642. DOI: 10.1016/j.peptides.2004.05.021Chang C.L., Roh J., Hsu S.Y.T. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides (N.Y.). 2004;25(10):1633–1642. DOI: 10.1016/j.peptides.2004.05.021Yang J.H., Jia Y.X., Pan C.S., et al. Effects of intermedin1-53 on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem. Biophys. Res. Commun. 2005;327(3):713–719. DOI: 10.1016/j.bbrc.2004.12.071Yang J.H., Jia Y.X., Pan C.S., et al. Effects of intermedin1-53 on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem. Biophys. Res. Commun. 2005;327(3):713–719. DOI: 10.1016/j.bbrc.2004.12.071Zhang S., Xu M., Wang X. Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases. Br. J. Pharmacol. 2018;175(8):1230–1240. DOI: 10.1111/bph.13814 EDN: YCYQAPZhang S., Xu M., Wang X. Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases. Br. J. Pharmacol. 2018;175(8):1230–1240. DOI: 10.1111/bph.13814 EDN: YCYQAPMorimoto R., Satoh F., Murakami O., et al. Expression of adrenomedullin2/intermedin in human brain, heart, and kidney. Peptides (N.Y.). 2007;28(5):1095–1103. DOI: 10.1016/j.peptides.2007.01.018Morimoto R., Satoh F., Murakami O., et al. Expression of adrenomedullin2/intermedin in human brain, heart, and kidney. Peptides (N.Y.). 2007;28(5):1095–1103. DOI: 10.1016/j.peptides.2007.01.018Takahashi K., Kikuchi K., Maruyama Y., et al. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney. Peptides (N.Y.). 2006;27(6):1383– 1389. DOI: 10.1016/j.peptides.2005.11.004Takahashi K., Kikuchi K., Maruyama Y., et al. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney. Peptides (N.Y.). 2006;27(6):1383– 1389. DOI: 10.1016/j.peptides.2005.11.004Naot D., Musson D.S., Cornish J. The Activity of Peptides of the Calcitonin Family in Bone. Physiol. Rev. 2019;99(1):781–805. DOI: 10.1152/physrev.00066.2017Naot D., Musson D.S., Cornish J. The Activity of Peptides of the Calcitonin Family in Bone. Physiol. Rev. 2019;99(1):781–805. DOI: 10.1152/physrev.00066.2017de Miranda D.C., de Oliveira Faria G., Hermidorff M.M., et al. Pre- and Post-Conditioning of the Heart: An Overview of Cardioprotective Signaling Pathways. Curr. Vasc. Pharmacol. 2021;19(5):499–524. DOI: 10.2174/1570161119666201120160619 EDN: WOOCBLde Miranda D.C., de Oliveira Faria G., Hermidorff M.M., et al. Pre- and Post-Conditioning of the Heart: An Overview of Cardioprotective Signaling Pathways. Curr. Vasc. Pharmacol. 2021;19(5):499–524. DOI: 10.2174/1570161119666201120160619 EDN: WOOCBLBell D., Campbell M., Ferguson M., et al. AM 1 -receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury. J. Physiol. 2012;590(5):1181–1197. DOI: 10.1113/jphysiol.2011.221895 EDN: UALXTBBell D., Campbell M., Ferguson M., et al. AM 1 -receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury. J. Physiol. 2012;590(5):1181–1197. DOI: 10.1113/jphysiol.2011.221895 EDN: UALXTBBell D., Campbell M., McAleer S.F., et al. Endothelium-derived intermedin/adrenomedullin-2 protects human ventricular cardiomyocytes from ischaemia-reoxygenation injury predominantly via the AM 1 receptor. Peptides (N.Y.). 2016;76:1–13. DOI: 10.1016/j.peptides.2015.12.005Bell D., Campbell M., McAleer S.F., et al. Endothelium-derived intermedin/adrenomedullin-2 protects human ventricular cardiomyocytes from ischaemia-reoxygenation injury predominantly via the AM 1 receptor. Peptides (N.Y.). 2016;76:1–13. DOI: 10.1016/j.peptides.2015.12.005Qin Y.W., Teng X., He J.Q., et al. Increased plasma levels of intermedin and brain natriuretic peptide associated with severity of coronary stenosis in acute coronary syndrome. Peptides (N.Y.). 2013;42:84–88. DOI: 10.1016/j.peptides.2013.01.011Qin Y.W., Teng X., He J.Q., et al. Increased plasma levels of intermedin and brain natriuretic peptide associated with severity of coronary stenosis in acute coronary syndrome. Peptides (N.Y.). 2013;42:84–88. DOI: 10.1016/j.peptides.2013.01.011Lv Z., Wu K., Chen X., et al. Plasma intermedin levels in patients with acute myocardial infarction. Peptides (N.Y.). 2013;43:121–125. DOI: 10.1016/j.peptides.2013.03.007Lv Z., Wu K., Chen X., et al. Plasma intermedin levels in patients with acute myocardial infarction. Peptides (N.Y.). 2013;43:121–125. DOI: 10.1016/j.peptides.2013.03.007Tang B., Zhong Z., Shen H.W., et al. Intermedin as a prognostic factor for major adverse cardiovascular events in patients with ST-segment elevation acute myocardial infarction. Peptides (N.Y.). 2014;58:98–102. DOI: 10.1016/j.peptides.2014.06.009Tang B., Zhong Z., Shen H.W., et al. Intermedin as a prognostic factor for major adverse cardiovascular events in patients with ST-segment elevation acute myocardial infarction. Peptides (N.Y.). 2014;58:98–102. DOI: 10.1016/j.peptides.2014.06.009Bell D., Gordon B.J., Lavery A., et al. Plasma levels of intermedin (adrenomedullin-2) in healthy human volunteers and patients with heart failure. Peptides (N.Y.). 2016;76:19–29. DOI: 10.1016/j.peptides.2015.12.003Bell D., Gordon B.J., Lavery A., et al. Plasma levels of intermedin (adrenomedullin-2) in healthy human volunteers and patients with heart failure. Peptides (N.Y.). 2016;76:19–29. DOI: 10.1016/j.peptides.2015.12.003Li P., Shi L., Han Y., et al. Prognostic Value of Plasma Intermedin Level in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Medicine. 2016;95(16):e3422. DOI: 10.1097/MD.0000000000003422Li P., Shi L., Han Y., et al. Prognostic Value of Plasma Intermedin Level in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Medicine. 2016;95(16):e3422. DOI: 10.1097/MD.0000000000003422Zhang H., Jiang W., Liu J.Y., et al. Intermedin is upregulated and has protective roles in a mouse ischemia/reperfusion model. Hyperten. Res. 2009;32(10):861–868. DOI: 10.1038/hr.2009.120Zhang H., Jiang W., Liu J.Y., et al. Intermedin is upregulated and has protective roles in a mouse ischemia/reperfusion model. Hyperten. Res. 2009;32(10):861–868. DOI: 10.1038/hr.2009.120Li H., Bian Y., Zhang N., et al. Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats. Cardiovasc. Diabetol. 2013;12(1):91. DOI: 10.1186/1475-2840-12-91 EDN: RIVCJHLi H., Bian Y., Zhang N., et al. Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats. Cardiovasc. Diabetol. 2013;12(1):91. DOI: 10.1186/1475-2840-12-91 EDN: RIVCJHYang S.M., Liu J., Li C.X. Intermedin protects against myocardial ischemia-reperfusion injury in hyperlipidemia rats. Genet. Mol. Res. 2014;13(4):8309–8319. DOI: 10.4238/2014.October.20.7Yang S.M., Liu J., Li C.X. Intermedin protects against myocardial ischemia-reperfusion injury in hyperlipidemia rats. Genet. Mol. Res. 2014;13(4):8309–8319. DOI: 10.4238/2014.October.20.7Teng X., Bian Y., Cai Y., et al. Downregulation of Endogenous Intermedin Augmented Myocardial Injury in Rats with Ischemia/Reperfusion. Hormone and Metabolic Research. 2013;45(3):206–212. DOI: 10.1055/s-0032-1327572Teng X., Bian Y., Cai Y., et al. Downregulation of Endogenous Intermedin Augmented Myocardial Injury in Rats with Ischemia/Reperfusion. Hormone and Metabolic Research. 2013;45(3):206–212. DOI: 10.1055/s-0032-1327572Song J.Q., Teng X., Cai Y., et al. Activation of Akt/GSK-3β signaling pathway is involved in intermedin1-53 protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis. 2009;14(9):1061–1069. DOI: 10.1007/s10495-009-0382-2 EDN: AZFCNFSong J.Q., Teng X., Cai Y., et al. Activation of Akt/GSK-3β signaling pathway is involved in intermedin1-53 protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis. 2009;14(9):1061–1069. DOI: 10.1007/s10495-009-0382-2 EDN: AZFCNFZhao L., Peng D.Q., Zhang J., et al. Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1-53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion. Peptides (N.Y.). 2012;33(2):329–335. DOI: 10.1016/j.peptides.2011.12.016 EDN: XZHMVNZhao L., Peng D.Q., Zhang J., et al. Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1-53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion. Peptides (N.Y.). 2012;33(2):329–335. DOI: 10.1016/j.peptides.2011.12.016 EDN: XZHMVNWei P., Yang X.J., Fu Q., et al. Intermedin attenuates myocardial infarction through activation of autophagy in a rat model of ischemic heart failure via both cAMP and MAPK/ERK1/2 pathways. Int. J. Clin. Exp. Pathol. 2015;8(9):9836–44. EDN: YZZXMPWei P., Yang X.J., Fu Q., et al. Intermedin attenuates myocardial infarction through activation of autophagy in a rat model of ischemic heart failure via both cAMP and MAPK/ERK1/2 pathways. Int. J. Clin. Exp. Pathol. 2015;8(9):9836–44. EDN: YZZXMPPopov S.V., Mukhomedzyanov A.V., Voronkov N.S., et al. Regulation of autophagy of the heart in ischemia and reperfusion. Apoptosis. 2023;28(1–2):55–80. DOI: 10.1007/s10495-022-01786-1 EDN: HCBZOIPopov S.V., Mukhomedzyanov A.V., Voronkov N.S., et al. Regulation of autophagy of the heart in ischemia and reperfusion. Apoptosis. 2023;28(1–2):55–80. DOI: 10.1007/s10495-022-01786-1 EDN: HCBZOILiao H., Wang Z., Zhang X., et al. Intermedin induces autophagy and attenuates hypoxia-induced injury in cardiomyocytes by regulation of MALAT1/ULK1. Peptides (N.Y.). 2023;160:170917. DOI: 10.1016/j.peptides.2022.170917 EDN: JUJBCILiao H., Wang Z., Zhang X., et al. Intermedin induces autophagy and attenuates hypoxia-induced injury in cardiomyocytes by regulation of MALAT1/ULK1. Peptides (N.Y.). 2023;160:170917. DOI: 10.1016/j.peptides.2022.170917 EDN: JUJBCIQiao X., Wang L., Wang Y., et al. Intermedin attenuates renal fibrosis by induction of heme oxygenase-1 in rats with unilateral ureteral obstruction. BMC Nephrol. 2017;18(1):232. DOI: 10.1186/s12882-017-0659-6 EDN: ARCXBPQiao X., Wang L., Wang Y., et al. Intermedin attenuates renal fibrosis by induction of heme oxygenase-1 in rats with unilateral ureteral obstruction. BMC Nephrol. 2017;18(1):232. DOI: 10.1186/s12882-017-0659-6 EDN: ARCXBPSmith R.S., Gao L., Bledsoe G., et al. Intermedin is a new angiogenic growth factor. Am. J. Physiol. Heart Circ. Physiol. 2009;297(3):H1040– H1047. DOI: 10.1152/ajpheart.00404.2009Smith R.S., Gao L., Bledsoe G., et al. Intermedin is a new angiogenic growth factor. Am. J. Physiol. Heart Circ. Physiol. 2009;297(3):H1040– H1047. DOI: 10.1152/ajpheart.00404.2009Jolly L., March J., Kemp P., et al. Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats. Br. J. Pharmacol. 2009;157(8):1502-1513. DOI: 10.1111/j.1476-5381.2009.00306.xJolly L., March J., Kemp P., et al. Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats. Br. J. Pharmacol. 2009;157(8):1502-1513. DOI: 10.1111/j.1476-5381.2009.00306.xDong F., Taylor M.M., Samson W.K., Ren J. Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C- and protein kinase A-dependent pathway in murine ventricular myocytes. J. Appl. Physiol. 2006;101(3):778–784. DOI: 10.1152/japplphysi-ol.01631.2005Dong F., Taylor M.M., Samson W.K., Ren J. Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C- and protein kinase A-dependent pathway in murine ventricular myocytes. J. Appl. Physiol. 2006;101(3):778–784. DOI: 10.1152/japplphysi-ol.01631.2005Kandilci H.B., Gumusel B., Lippton H. Intermedin/adrenomedullin-2 (IMD/AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent pathway: Role of nitric oxide and large conductance calcium-activated potassium channels (BKCa). Peptides (N.Y.). 2008;29(8):1321– 1328. DOI: 10.1016/j.peptides.2008.04.008Kandilci H.B., Gumusel B., Lippton H. Intermedin/adrenomedullin-2 (IMD/AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent pathway: Role of nitric oxide and large conductance calcium-activated potassium channels (BKCa). Peptides (N.Y.). 2008;29(8):1321– 1328. DOI: 10.1016/j.peptides.2008.04.008Gong Y.S., Fan X.F., Wu X.M., et al. Changes of intermedin/adreno-medullin 2 and its receptors in the right ventricle of rats with chronic hypoxic pulmonary hypertension. Sheng Li Xue Bao. 2007;59(2):210–214. PMID: 17437045Gong Y.S., Fan X.F., Wu X.M., et al. Changes of intermedin/adreno-medullin 2 and its receptors in the right ventricle of rats with chronic hypoxic pulmonary hypertension. Sheng Li Xue Bao. 2007;59(2):210–214. PMID: 17437045Naryzhnaya N.V., Maslov L.N., Derkachev I.A., et al. The effect of an adaptation to hypoxia on cardiac tolerance to ischemia/reperfusion. J. Biomed. Res. 2022;37(4):230–254. DOI: 10.7555/JBR.36.20220125 EDN: VNFGODNaryzhnaya N.V., Maslov L.N., Derkachev I.A., et al. The effect of an adaptation to hypoxia on cardiac tolerance to ischemia/reperfusion. J. Biomed. Res. 2022;37(4):230–254. DOI: 10.7555/JBR.36.20220125 EDN: VNFGODBurtscher J., Citherlet T., Camacho-Cardenosa A., et al. Mechanisms underlying the health benefits of intermittent hypoxia conditioning. J. Physiol. 2023. DOI: 10.1113/JP285230 EDN: JIQKRXBurtscher J., Citherlet T., Camacho-Cardenosa A., et al. Mechanisms underlying the health benefits of intermittent hypoxia conditioning. J. Physiol. 2023. DOI: 10.1113/JP285230 EDN: JIQKRXRybnikova E., Lukyanova L. Molecular Mechanisms of Adaptation to Hypoxia. Int. J. Mol. Sci. 2023;24(5):4563. DOI: 10.3390/ijms24054563 EDN: MMAECIRybnikova E., Lukyanova L. Molecular Mechanisms of Adaptation to Hypoxia. Int. J. Mol. Sci. 2023;24(5):4563. DOI: 10.3390/ijms24054563 EDN: MMAECIMaslov L.N., Popov S.V., Naryzhnaya N.V., et al. The regulation of necroptosis and perspectives for the development of new drugs preventing ischemic/reperfusion of cardiac injury. Apoptosis. 2022;27 (9–10):697–719. DOI: 10.1007/s10495-022-01760-x EDN: EGRPIZMaslov L.N., Popov S.V., Naryzhnaya N.V., et al. The regulation of necroptosis and perspectives for the development of new drugs preventing ischemic/reperfusion of cardiac injury. Apoptosis. 2022;27 (9–10):697–719. DOI: 10.1007/s10495-022-01760-x EDN: EGRPIZNaryzhnaya N.V., Maslov L.N., Popov S.V., et al. Pyroptosis is a drug target for prevention of adverse cardiac remodeling: The crosstalk between pyroptosis, apoptosis, and autophagy. J. Biomed. Res. 2022;36(6):375–389. DOI: 10.7555/JBR.36.20220123 EDN: RKIQLPNaryzhnaya N.V., Maslov L.N., Popov S.V., et al. Pyroptosis is a drug target for prevention of adverse cardiac remodeling: The crosstalk between pyroptosis, apoptosis, and autophagy. J. Biomed. Res. 2022;36(6):375–389. DOI: 10.7555/JBR.36.20220123 EDN: RKIQLPFang X., Ardehali H., Min J., Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat. Rev. Cardiol. 2023;20(1):7–23. DOI: 10.1038/s41569-022-00735-4 EDN: SY-WGJHFang X., Ardehali H., Min J., Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat. Rev. Cardiol. 2023;20(1):7–23. DOI: 10.1038/s41569-022-00735-4 EDN: SYWGJH

The authors declare that there are no conflicts of interest present.